# Global Immunoassay Market Size, Share, Trends, and Forecast, 2026-2033 | Precision Medicine and Point-of-Care Diagnostics Drive 4.63% CAGR Toward USD 40.25 Billion

- Published: 2026-11-17
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/global-immunoassay-market-size-share-trends-and-forecast-2026-2033-precision-medicine-and/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Precision medicine, rising chronic disease prevalence and drug development integration drive immunoassay adoption, improving treatment efficacy and patient outcomes.*

Dublin, Nov. 17, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/5415506/immunoassay-market-size-share-and-trends-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=5z7q83&amp;utm_campaign=2404756+-+Global+Immunoassay+Market+Size%2c+Share%2c+Trends%2c+and+Forecast%2c+2026-2033+%7c+Precision+Medicine+and+Point-of-Care+Diagnostics+Drive+4.63%25+CAGR+Toward+USD+40.25+Billion&amp;utm_exec=clshmsai" rel="nofollow">"Immunoassay Market Size, Share & Trends Analysis Report by Product, Technology, Application, End-use, Specimen, Region, and Segment Forecasts, 2026-2033"</a> has been added to **ResearchAndMarkets.com's** offering.

The global immunoassay market was valued at an estimated USD 28.05 billion in 2025 and is projected to reach USD 40.25 billion by 2033. The market is expected to expand at a compound annual growth rate (CAGR) of 4.63% from 2026 to 2033, supported by rising demand for precision medicine, targeted therapies, advanced diagnostic testing, and biomarker-based treatment selection.

Immunoassays are increasingly important in personalized medicine because they enable healthcare professionals to identify biomarkers associated with patient responses to specific therapies. Their use supports more informed treatment decisions, improves therapeutic efficacy, and reduces the risk of adverse effects. The continued shift from a one-size-fits-all treatment model toward individualized care is therefore expected to remain a significant driver of immunoassay market growth.

The increasing prevalence of cancer, cardiovascular diseases, autoimmune disorders, endocrine conditions, and infectious diseases is also strengthening demand for immunoassay technologies. Oncology and cardiology applications are benefiting from the need for earlier disease detection, treatment monitoring, and patient stratification. In addition, therapeutic drug monitoring is gaining importance as healthcare providers seek to optimize dosage, evaluate treatment response, and improve clinical outcomes.

Pharmaceutical and biotechnology companies are incorporating immunoassays into drug discovery and development pipelines to support biomarker validation, clinical trial design, safety assessment, and therapeutic monitoring. This integration can improve the probability of successful drug development while accelerating the advancement of novel therapeutics. Continued investment in automated analyzers, high-performance reagents, rapid testing platforms, and laboratory software is expected to create further opportunities across the global immunoassay market.

**Market Segmentation Covered in the Report**

The report provides revenue forecasts at global, regional, and country levels and evaluates industry trends across sub-segments from 2021 to 2033. Market analysis is organized by product, application, technology, specimen, end-use, and region.

-   **Product:** Reagents & Kits, including ELISA Reagents & Kits, Rapid Tests Reagents & Kits, ELISPOT Reagents & Kits, Western Blot Reagents & Kits, and Other Reagents & Kits; Analyzers/Instruments, including Open-Ended Systems and Closed-Ended Systems; and Software & Services.
-   **Application:** Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease Testing, Autoimmune Diseases, and Others.
-   **Technology:** Radioimmunoassay (RIA), Enzyme Immunoassays (EIA), Chemiluminescence Immunoassays (CLIA), Fluorescence Immunoassays (FIA), Rapid Test, and Others.
-   **Specimen:** Blood, Saliva, Urine, and Others.
-   **End-use:** Hospitals, Blood Banks, Clinical Laboratories, Pharmaceutical and Biotech Companies, Academic Research Centers, and Others.

**Regional Market Coverage**

The regional assessment covers North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa (MEA). Country-level analysis includes the U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, China, Japan, India, Australia, South Korea, Thailand, Brazil, Argentina, South Africa, Saudi Arabia, UAE, and Kuwait.

North America and Europe remain important markets due to established diagnostic infrastructure, extensive clinical research activity, and strong adoption of precision medicine. Asia-Pacific is expected to offer notable growth opportunities as healthcare investment increases, laboratory capacity expands, and demand rises for advanced diagnostic technologies. Latin America and the Middle East and Africa (MEA) are also positioned for development as access to testing improves and public and private healthcare systems modernize.

Overall, growing demand for accurate diagnostics, biomarker-guided therapies, automated testing, and personalized treatment strategies is expected to support steady global immunoassay market expansion through 2033.

**Key Attributes:**  
  

| Report Attribute | Details |
| --- | --- |
| No. of Pages | 190 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value (USD) in 2025 | $28.05 Billion |
| Forecasted Market Value (USD) by 2033 | $40.25 Billion |
| Compound Annual Growth Rate | 4.6% |
| Regions Covered | Global |

  
**Key Topics Covered:**

**Chapter 1. Methodology and Scope**  
1.1. Market Segmentation and Scope  
1.2. Market Definitions  
1.3. Research Methodology  
1.3.1. Information Procurement  
1.3.2. Information or Data Analysis  
1.3.3. Market Formulation & Data Visualization  
1.3.4. Data Validation & Publishing  
1.4. Research Scope and Assumptions  
1.4.1. List of Data Sources  
  
**Chapter 2. Executive Summary**  
2.1. Market Outlook  
2.2. Segment Outlook  
2.3. Competitive Insights  
  
**Chapter 3. Immunoassay Market Variables, Trends, & Scope**  
3.1. Market Introduction/Lineage Outlook  
3.2. Market Size and Growth Prospects (USD Million)  
3.3. Market Dynamics  
3.3.1. Market Drivers Analysis  
3.3.1.1. Rising incidence of chronic and infectious diseases  
3.3.1.2. Increasing demand for point-of-care diagnostics  
3.3.1.3. Growing demand for portable and automated immunoassays  
3.3.2. Market Restraints Analysis  
3.3.2.1. Lower detection limit  
3.3.2.2. Limitations associated with immunoassay techniques  
3.4. Immunoassay Market Analysis Tools  
3.4.1. Porter's Five Forces Analysis  
3.4.1.1. Bargaining power of the suppliers  
3.4.1.2. Bargaining power of the buyers  
3.4.1.3. Threats of substitution  
3.4.1.4. Threats from new entrants  
3.4.1.5. Competitive rivalry  
3.4.2. PESTEL Analysis  
3.4.2.1. Political landscape  
3.4.2.2. Economic and Social landscape  
3.4.2.3. Technological landscape  
3.4.2.4. Environmental landscape  
3.4.2.5. Legal landscape  
  
**Chapter 4. Immunoassay Market: Product Estimates & Trend Analysis**  
4.1. Immunoassay Market: Product Movement Analysis  
4.2. Immunoassay Market Estimates and Forecasts, by Product (USD Million), 2025 & 2033  
4.3. Assays, Kits, and Reagents  
4.3.1. ELISA Reagents & Kits  
4.3.2. Rapid Tests Reagents & Kits  
4.3.3. ELISPOT Reagents & Kits  
4.3.4. Western Blot Reagents & Kits  
4.3.5. Other Reagents & Kits  
4.4. Analyzers/Instruments  
4.4.1. Open Ended Systems  
4.4.2. Closed Ended Systems  
4.5. Software and Services  
4.6. Market Revenue Estimates and Forecasts for Product Segments, 2021 - 2033 (USD Million)  
  
**Chapter 5. Immunoassay Market: Application Estimates & Trend Analysis**  
5.1. Immunoassay Market: Application Movement Analysis  
5.2. Immunoassay Market Estimates and Forecasts, by Application (USD Million), 2025 & 2033  
5.3. Therapeutic Drug Monitoring  
5.4. Oncology  
5.5. Cardiology  
5.6. Endocrinology  
5.7. Infectious Disease Testing  
5.8. Autoimmune Diseases  
5.9. Others  
5.10. Market Revenue Estimates and Forecasts for Application Segments, 2021 - 2033 (USD Million)  
  
**Chapter 6. Immunoassay Market: Technology Estimates & Trend Analysis**  
6.1. Immunoassay Market: Technology Movement Analysis  
6.2. Immunoassay Market Estimates and Forecasts, by Technology (USD Million), 2025 & 2033  
6.3. Radioimmunoassay (RIA)  
6.4. Enzyme Immunoassays (EIA)  
6.4.1. Chemiluminescence Immunoassays (CLIA)  
6.4.2. Fluorescence Immunoassays (FIA)  
6.5. Rapid Test  
6.6. Others  
6.7. Market Revenue Estimates and Forecasts for Technology Segments, 2021 - 2033 (USD Million)  
  
**Chapter 7. Immunoassay Market: Specimen Estimates & Trend Analysis**  
7.1. Immunoassay Market: Specimen Movement Analysis  
7.2. Immunoassay Market Estimates and Forecasts, by Specimen (USD Million), 2025 & 2033  
7.3. Blood  
7.4. Saliva  
7.5. Urine  
7.6. Others  
7.7. Market Revenue Estimates and Forecasts for Specimen Segments, 2021 - 2033 (USD Million)  
  
**Chapter 8. Immunoassay Market: End Use Estimates & Trend Analysis**  
8.1. Immunoassay Market: End-use Movement Analysis  
8.2. Immunoassay Market Estimates and Forecasts, by End Use (USD Million), 2025 & 2033  
8.3. Hospitals  
8.4. Blood Banks  
8.5. Clinical Laboratories  
8.6. Pharmaceutical and Biotech Companies  
8.7. Academic Research Centers  
8.8. Others  
8.9. Market Revenue Estimates and Forecasts for End Use Segments, 2021 - 2033 (USD Million)  
  
**Chapter 9. Immunoassay Market: Regional Estimates & Trend Analysis**  
9.1. Immunoassay Market Share, By Region, 2025 & 2033, USD Million  
9.2. Regional and Country Market Estimates and Forecasts, 2021 - 2033 (USD Million)  
9.3. Country Analysis Framework  
9.3.1. Key Country Dynamics  
9.3.2. Target Disease Prevalence  
9.3.3. Competitive Scenario  
9.3.4. Regulatory Framework  
9.3.5. Reimbursement Scenario  
9.4. North America  
9.4.1. U.S.  
9.4.2. Canada  
9.4.3. Mexico  
9.5. Europe  
9.5.1. UK  
9.5.2. Germany  
9.5.3. France  
9.5.4. Italy  
9.5.5. Spain  
9.5.6. Denmark  
9.5.7. Sweden  
9.5.8. Norway  
9.6. Asia Pacific  
9.6.1. Japan  
9.6.2. China  
9.6.3. India  
9.6.4. Australia  
9.6.5. South Korea  
9.6.6. Thailand  
9.7. Latin America  
9.7.1. Brazil  
9.7.2. Argentina  
9.8. Middle East and Africa  
9.8.1. South Africa  
9.8.2. Saudi Arabia  
9.8.3. UAE  
9.8.4. Kuwait  
  
**Chapter 10. Competitive Landscape**  
10.1. Recent Developments & Impact Analysis by Key Market Participants  
10.2. Company Categorization  
10.3. Company Heat Map Analysis  
10.4. Company Profile Framework  
10.4.1. Participant's Overview  
10.4.2. Financial Performance  
10.4.3. Product Benchmarking  
10.4.4. Recent Developments/ Strategic Initiatives  
10.5. Abbott  
10.6. Siemens Healthineers AG  
10.7. Danaher Corporation (Beckman Coulter)  
10.8. bioMerieux SA  
10.9. Quidel Corporation  
10.10. Sysmex Corporation  
10.11. Ortho Clinical Diagnostics  
10.12. Bio-Rad Laboratories, Inc.  
10.13. F. Hoffmann-La Roche AG  
10.14. Becton, Dickinson, and Company  
10.15. Thermo Fisher Scientific, Inc.  
  
**List of Tables \[152\]**  
  
**List of Figures \[104\]**

**Companies Featured**

-   Abbott
-   Siemens Healthineers
-   Danaher Corporation (Beckman Coulter)
-   bioMerieux SA
-   Quidel Corporation
-   Sysmex Corporation
-   Ortho Clinical Diagnostics
-   Bio-Rad Laboratories, Inc.
-   F. Hoffmann-La Roche AG
-   Becton, Dickinson, and Company
-   Thermo Fisher Scientific, Inc.

For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5415506/immunoassay-market-size-share-and-trends-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=5z7q83&amp;utm_campaign=2404756+-+Global+Immunoassay+Market+Size%2c+Share%2c+Trends%2c+and+Forecast%2c+2026-2033+%7c+Precision+Medicine+and+Point-of-Care+Diagnostics+Drive+4.63%25+CAGR+Toward+USD+40.25+Billion&amp;utm_exec=clshmsai" rel="nofollow">https://www.researchandmarkets.com/r/lxz48n</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/MWY4YTM4ZDMtMzg0NC00ZDZiLWIzNTUtMjhhMTI1Y2M0OTYzLTEwMjY3MzctMjAyNi0xMS0xNy1lbg==/tiny/Research-and-Markets.png)

## Related

- [Medical Oxygen Systems Market Size, Share, Trends, Industry Analysis - Global Forecast to 2036 | Market to Reach $24.36 Billion as Managed Services and On-Site Generation Drive 6.4% CAGR](https://healthcarenews.io/news/medical-oxygen-systems-market-size-share-trends-industry-analysis-global-forecast-to-2036.md)
- [Global Anatomic Pathology Market Size, Share, Trends, and Forecast, 2026-2033 | AI and Precision Oncology Drive 8.09% CAGR, Unlocking a $71.68 Billion Market](https://healthcarenews.io/news/global-anatomic-pathology-market-size-share-trends-and-forecast-2026-2033-ai-and-precision.md)
- [aequum Releases New White Paper Helping Brokers Deliver Cost Containment Strategies That Hold Up Under Real-World Pressure](https://healthcarenews.io/news/aequum-releases-new-white-paper-helping-brokers-deliver-cost-containment-strategies-that-h.md)
- [Drug and Gene Delivery Devices - Global Strategic Business Report 2026: Capitalize on 8.1% CAGR to Secure the $1.2 Billion Market by 2032 as AbbVie, Moderna, Pfizer and Novartis Accelerate](https://healthcarenews.io/news/drug-and-gene-delivery-devices-global-strategic-business-report-2026-capitalize-on-8-1-cag.md)
